| Document |
Document Title |
|
WO/2015/193911A1 |
The present invention relates to a process for the preparation of 2-(trihalomethyl) benzamide from a 2-(trihalomethyl) benzoyl chloride in the presence of isopropanol or cold water.
|
|
WO/2015/193255A1 |
The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.
|
|
WO/2015/192282A1 |
The present invention mainly pertains to a catalytic process for preparing a formamide,comprising reacting a formic acid ester with an aromatic amine carrying at least one electron withdrawing group in the presence of a catalyst of fluor...
|
|
WO/2015/192324A1 |
An anthraquinone compound which is suitable for forming a color filter used for a liquid crystal display device, acomposition containing a resin and the anthraquinone compound, an article having a polymer layer formed from the compositio...
|
|
WO/2015/191430A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such molecules and intermediates used in such processes, compositions containi...
|
|
WO/2015/188152A1 |
Described herein are compounds that are EP4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP4 receptors.
|
|
WO/2015/184542A1 |
The present application relates to novel compounds comprising a moiety that leads to the metabolic production of ketones bonded to a ketone- potentiated anti-epileptic drug, compositions comprising these compounds, and their use, for exa...
|
|
WO/2015/177537A1 |
The present invention relates to a novel process for the synthesis of polycyclic carbamoyl pyridone derivativesof formula (B): wherein Ar, W1, W2, W3, X, Y and Z are as defined in the specification; and to novel chemical intermediates fo...
|
|
WO/2015/173813A1 |
The present invention relates to pharmaceutical composition comprising one or more stereoisomers of N-(1-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide for the the treatment of type II diabetes and/or other medic...
|
|
WO/2015/174747A1 |
The present invention relates to: coralmycin A and B, which are novel compounds exhibiting antibacterial activity, an isomer thereof, a derivative thereof or a pharmaceutically acceptable salt thereof; a Corallococcus sp. strain producin...
|
|
WO/2015/174300A1 |
Provided are a compound for gelling or thickening a fluid organic substance to the desired viscosity or for uniformly stabilizing a composition containing a fluid organic substance, a thickening stabilizer including the compound, a thick...
|
|
WO/2015/171792A1 |
Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA- specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific Ti contrast enhancement ...
|
|
WO/2015/168031A1 |
The present invention provides a buprenorphine dimer compound, wherein the two buprenorphine portions are linked via an ethylene spacer, wherein the spacer is bonded to the two opioid molecules via an ether bond. Pharmaceutical compositi...
|
|
WO/2015/168014A1 |
Pharmaceutically active homo-dimers of opioid and other pharmaceutically active agents characterized by a single phenolic hydroxyl group wherein the respective monomers are ether-linked through such groups by an ethylene residue. The dim...
|
|
WO/2015/165352A1 |
The present invention provides a compound with a structure represented by general formula I or a pharmaceutically acceptable salt thereof, a preparation method for the compound or the salt, and a use of the compound or the pharmaceutical...
|
|
WO/2015/162144A1 |
The invention relates to a novel method for producing substituted biphenylamides of general formula (V), characterized in that anilides of formula (II) are reacted in a solvent which is different from tetrahydrofuran, having an organobor...
|
|
WO/2015/158204A1 |
The present invention relates to amide derivatives and pharmaceutically acceptable salts thereof, preparation method therefor and medicinal application thereof. Specifically, the present invention relates to amide derivatives represented...
|
|
WO/2015/160307A1 |
There is provided a compound of formula I, having the structure: wherein R1 to R5 have the meanings given in the description.
|
|
WO/2015/156251A1 |
The present invention pertains to a method for producing a vinyl-amine-unit-containing polymer, the method having a step for preparing a mixture for polymerization (a) that contains N-vinylformamide as a monomer component by using crude ...
|
|
WO/2015/157057A1 |
The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.
|
|
WO/2015/156346A1 |
Provided is a method for producing a synthetic intermediate of a heterocyclic compound having a renin inhibitory activity and effective as a prophylactic or therapeutic drug against diabetic renal disease, hypertension, and the like. A m...
|
|
WO/2015/154673A1 |
The invention relates a pharmaceutical composition comprising (i) prodrugs of NEP inhibitors, (ii) mutual prodrugs of angiotensin receptor antagonist and a NEP inhibitor, (iii) a combination of an angiotensin receptor antagonist prodrug ...
|
|
WO/2015/155664A1 |
The present invention relates to an improved process for the preparation of pure 2-(2- amino-1,3-thiazol-4-yl)-N-[4-(2-[(2R)-2-hydroxy-2-phenylethy
l]amino]ethylphenyl]- acetamide of formula (1) substantially free of impurities. The pres...
|
|
WO/2015/151005A2 |
The invention relates specifically to the chemical synthesis, identification and determination of the chemical structure of analogues of the caffeic acid phenethyl ester (CAPE) with activity against cancer, especially against liver cance...
|
|
WO/2015/153516A1 |
The instant invention describes hydrazide-containing compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiat...
|
|
WO/2015/148880A1 |
The present application discloses an efficient process for the preparation of N-acetyl-L-cysteine amide (NACA) starting with N-acetyl-L-cysteine.
|
|
WO/2015/142928A1 |
The invention relates to administration of various pharmaceutical formulations of N- (4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluor
ophenyl)cyclopropane-1,1- dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metaboli...
|
|
WO/2015/141585A1 |
Provided are an oligoaniline derivative represented by formula (1), a charge-transporting varnish comprising the oligoaniline derivative, and an organic EL element. (In the formula, R1 is a hydrogen atom or optionally substituted alkyl g...
|
|
WO/2015/137289A1 |
The present invention pertains to spherical water-dispersible amorphous particles having a particle diameter of 10-990 nm and a PDI of 0.01-0.5, wherein the amorphous particles contain an organic compound having a molecular weight of 50-...
|
|
WO/2015/134973A1 |
A series of phenelzine analogs comprising a phenelzine scaffold linked to an aromatic moiety and their use as inhibitors of lysine-specific demethylase 1 (LSD1) and/or one or more histone deacetylases (HDACs) is provided. The presently d...
|
|
WO/2015/133511A1 |
Provided is an endoparasite control agent that includes, as an active ingredient, a carboxamide derivative represented by general formula (I) or salts thereof in order to provide a novel endoparasite control agent such as an insecticide ...
|
|
WO/2015/129813A1 |
The present invention provides: a deuteration method that is both cost effective and has an excellent deuteration rate; a method for selectively replacing a leaving group of an aromatic compound with deuterium; and a deuteration catalyst...
|
|
WO/2015/129832A1 |
The present invention is a radiosensitive resin composition containing: a polymer having a structural unit that contains the group represented by formula (1); and a radiosensitive acid generator. In formula (1), R1 is a substituted or un...
|
|
WO/2015/129860A1 |
The present invention provides a therapeutic agent useful in the treatment and/or prevention of conditions, including cancer, caused by enhanced OPN production, the therapeutic agent containing a compound represented by the formula (in t...
|
|
WO/2015/121357A1 |
The invention relates to a method for hydrogenating carbon dioxide into a formamide, comprising the following steps: providing an organic phase, comprising an organic solvent and a catalyst dissolved or suspended in the organic solvent, ...
|
|
WO/2015/122494A1 |
Provided is a novel compound having an excellent suppression action against arrhythmia including atrial fibrillation and being useful as a pharmaceutical product having a separated antiviral effect. A compound indicated by general formul...
|
|
WO/2015/116968A1 |
The potency of a series of Hexamethylene bis-acetamide (HMBA) derivatives of formula I, that induce Hexamethylene bis-acetamide inducible protein 1 (HEXIM1 ) was determined in cancer cells. The method of inducing HEXIM1 expression and ce...
|
|
WO/2015/114157A1 |
The present invention relates to cyclopent(adi)ene compounds of formula (I) wherein the variables are as defined in the claims and description. The compounds are useful for combating or controlling invertebrate pests, in particular arthr...
|
|
WO/2015/110502A1 |
A composition comprising a polymer, or an oligomer, comprising cross-linking moiety, which moiety comprises a carbon-carbon triple bond; and a molecule comprising a carbon-carbon triple bond, wherein the thermal curing behavior of said m...
|
|
WO/2015/103901A1 |
Disclosed is a stearoyl amino acid salt. The stearoyl amino acid salt has a structural formula represented by a general formula (I), R1 indicating H or an aromatic base capable of substituted by one or more substituents, or C1-4 straight...
|
|
WO/2015/100235A1 |
Allosteric hemoglobin (Hb) modifiers of hemoglobin which contain nitric oxide (NO) moieties allowing for the release of NO in vivo. The compounds retain the oxygen delivery capability of the allosteric hemoglobin modifier to bind Hb and ...
|
|
WO/2015/099126A1 |
A method for producing (2S,5S)/(2R,5R)-5-hydroxypiperidine-2-carboxylic acid indicated by formula (10), the method being characterized in including a step for removing protection from hydroxyl groups in a compound represented by formula ...
|
|
WO/2015/094912A1 |
The present invention provides a compound of the Formula I: wherein A is: and W, Y, X, R1, R2, R3, and R4 are as defined herein, or a pharmaceutically acceptable salt thereof, for use as an inhibitor of the EP4 receptor.
|
|
WO/2015/091978A1 |
The present invention relates to a catalyst composition comprising the compound represented by Formula (I) as an internal electron donor, Formula I wherein: R1, R2, R3, R4, R5 and R6 are the same or different and are independently select...
|
|
WO/2015/089639A1 |
The present application is directed to excimer forming compounds of Formula I: W-V-[Y]n wherein W is an excimer forming fluorophore, V is a linker moiety, Y is a metal ion coordinating moiety and n is 1, 2 or 3. In particular, the applic...
|
|
WO/2015/086659A1 |
A lithographic printing plate precursor is disclosed including i) a support having a hydrophilic surface or which is provided with a hydrophilic layer, and (ii) a coating including a photopolymerisable layer, characterised in that the ph...
|
|
WO/2015/083740A1 |
Provided are: a compound that uniformly stabilizes a composition containing a fluid organic substance, or thickens or gels the fluid organic substance to a desired viscosity; a thickener/stabilizer containing the compound; a thickened/st...
|
|
WO/2015/082938A1 |
The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof : (I) wherein: n is 0 or 1; R1 is selected from H, alkyl and aralkyl, wherein said alkyl and aralkyl groups may be optionally substit...
|
|
WO/2015/076296A1 |
The present invention relates to: a bromine-containing N-phenyldi(meth)acrylimide derivative represented by general formula (1) (wherein R1, R2, m and k are as described in the description and claims), which is useful as a reactive flame...
|
|
WO/2015/073648A1 |
Amines and amine derivatives that improve the buffering range, and / or reduce the chelation and other negative interactions of the buffer and the system to be buffered. The reaction of amines or polyamines with various molecules to form...
|
